Dishman Carbogen Amcis Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2025 ,inter alia, to consider and approve the Audited Financial ....

EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

DCAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹215.10

prior close

₹216.13

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-1.5% vs market

Pharmaceuticals peers, median of 150sector+0.2%-0.9% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.0

15m

-0.0

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.8-1.5+0.2-0.9

Next day

+0.7+2.0-1.3+1.1-0.4

+1.4+0.9+0.5+0.1+1.3

+2.4+1.7+0.7+1.0+1.4

+12.5+1.6+10.9+1.2+11.4

+16.9+2.2+14.7+0.7+16.2

+24.7+2.7+22.0+1.2+23.6

15d

+24.1+4.5+19.6+0.6+23.5

+26.9+5.6+21.3+2.1+24.9

+22.3+9.0+13.3+3.8+18.5

+21.8+3.5+18.3-1.0+22.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dishman Carbogen Amcis has informed stock exchanges that its Board of Directors will meet on 21st May 2025 to consider, take on record, and approve the Audited Financial Results for the quarter and full year ended 31st March 2025. This is a routine advance intimation filed under SEBI LODR Regulations 29 and 50. The trading window for dealing in company securities, which was closed from 1st April 2025 to 23rd May 2025, will reopen from 24th May 2025 for directors, designated persons, and their immediate relatives.

Likely market impact

No immediate impact on shareholders or stock price as this is a procedural intimation. Investors should watch for the actual audited results on 21st May 2025 for insights into FY25 performance and any dividend recommendation.

By the numbersConsolidated · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹716.3 Cr	₹654.7 Cr	+9.4%
Operating profit	₹31.48 Cr	−₹53.27 Cr	turned positive
Profit after tax	₹43.09 Cr	−₹69.92 Cr	turned positive
EBITDA margin	19.7%	9.1%	+10.6 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.